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Abstract
The 2006 Cold Spring Harbor Laboratory meeting on the Mechanisms and Models of Cancer was
held August 16–20. The meeting featured several hundred presentations of many short talks
(mostly selected from the abstracts) and posters, with the airing of a number of exciting new
discoveries. We will focus this meeting review on models of cancer (primarily mouse models),
highlighting recent advances in new mouse models that better recapitulate sporadic tumorigenesis,
demonstrations of tumor addiction to tumor suppressor inactivation, new insight into senescence
as a tumor barrier, improved understanding of the evolutionary paths of cancer development, and
environmental/immunological influences on cancer.
Background
New mouse models: keeping it real
Traditional mouse models of cancers initiated by onco-
gene activation or tumor suppressor inactivation have
yielded valuable insight into tumorigenesis, but have suf-
fered from concerns that the mutation in either all cells of
the mouse or in all cells of a particular tissue fails to prop-
erly recapitulate natural cancer initiation. In the last few
years, new models have been developed that rely on Cre
recombinase mediated deletion of floxed sequences to
activate an oncogene or inactivate a tumor suppressor in
only a subset of cells of a tissue at a defined point in time.
Published studies have used Cre mediated activation of
mutant K-Ras (by removal of STOP sequences), with or
without similar mutation in p53, to generate models of
lung adenocarcinoma in mice [1-3]. These and similar
models are more relevant to spontaneous tumorigenesis,
as cells bearing the mutation are surrounded by non-
oncogenically mutated competitors, and there are reduced
concerns for developmental compensation effects associ-
ated with standard knockout or transgenic models.
Analogous to the Ras model, D. Dankort (A. McMahon
lab) showed that activation of oncogenic BRAFV600E via
adenoviral delivery of the Cre recombinase in the mouse
lung leads to frequent neoplastic lesions, albeit benign
with proliferation indexes that decrease with time, sug-
gesting that additional oncogenic hits are required for
progression to full malignancy. A. Puzio (C. Abate-Shen
lab) developed a mouse model for bladder carcinoma,
histologically similar to the human disease, using adeno-
viral delivery of Cre to induce simultaneous p53 and
PTEN deletion in the bladder in vivo. As will be discussed
in the next section, conditional models for gene inactiva-
tion can also be used to determine the importance of
maintaining tumor suppressor inactivation in an estab-
lished tumor.
While stem cells are thought to represent the targets for
tumorigenesis for at least some cancers, more committed
progenitors may also be targets, particularly if early muta-
tions confer self-renewal. R. Wechsler-Reya showed that
conditional deletion of Patched (resulting in activation of
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the Hedgehog pathway) in lineage-restricted granule neu-
ron precursors (GNPs), while not sufficient for transfor-
mation of all cells, does lead to medulloblastomas in all
mice. Thus, these cancers can arise in more lineage-
restricted neuronal progenitors, although further studies
will be needed to determine whether they actually do in
humans. Unlike the Lox-Cre models discussed above,
Patched should be deleted in most GNPs, and since GNPs
without Patched are continuously replenished, there is
ample opportunity for additional mutations that result in
transformation.
Exploiting the tumor addiction to p53 
inactivation
Genetic analysis of cancers reveals a number of defined
mutational events that appear specific for particular can-
cers, indicating that cancers follow certain evolutionary
paths. However, the fact that a particular mutation is
selected at a certain step in cancer development does not
necessarily imply that the same mutation is required for
tumor maintenance. The question of whether a particular
mutation is important for maintaining a full-blown
malignancy is important not only for understanding the
biology of cancer, but also for devising rational treatment
strategies. For several oncogenes the requirement for
maintenance of an initiating mutation for cancer viability
has been experimentally demonstrated, leading to the
term "oncogene addiction" [4], and thus making these
mutants attractive therapeutic targets. However, a similar
dependency has thus far not been documented for tumor
suppressor genes. Addressing this deficiency, several pres-
entations at this meeting demonstrated that tumor cells
must maintain mutant p53 to survive and proliferate.
C. Martins (G. Evan lab)explored the importance of loss
of p53 function for leukemia maintenance using
tamoxifen (TAM)-inducible p53 (p53ERTAM) [5] in spon-
taneous leukemias arising in Eμ-Myc transgenic mice in a
p53ER/+ background. These Eμ-Myc induced lymphomas
typically disable the p53 pathway. Thus, tumors arise in
an initially functional p53 background, with p53 disrup-
tion selected for during lymphoma progression. Restora-
tion of p53 function by TAM (allows apparently normal
p53 activity to be produced from the p53 ER allele)
induces rapid apoptosis in leukemic cells, but eventually
leads to selection of escapees that are insensitive to p53
restoration. Combining p53 restoration with extrinsic p53
activation stimuli (γ-irradiation) leads to substantial
improvement in inhibition of cancer progression.
A. Ventura (T. Jacks lab) employed a knock-in mouse
experimental system, where endogenous p53 expression
was prevented by Lox-flanked transcriptional termination
sequences, in order to address the consequence of re-
expressing p53 in spontaneous or irradiation induced
malignancies that arise on a p53 null background. In this
system, endogenous p53 expression can be restored by
action of Cre recombinase conditionally activated by
tamoxifen expression. Restoration of p53 expression led
to dramatic inhibition of tumor progression and regres-
sion of the tumors. Interestingly, the effect of p53 restora-
tion appeared to be tissue specific: p53 re-expression in
lymphomas induced rapid apoptosis, while in carcinomas
it induced permanent senescent-like arrest. In both cases,
restoration of p53 function delivered a fatal blow to the
tumor.
Two reports from S. Lowe's lab reached similar conclu-
sions using conditional expression of an shRNA against
p53. W. Xue used a liver progenitor cell transplant model
developed by L. Zender in the Lowe lab [6] to explore the
dependence of liver carcinoma induced by oncogenic Ras
expression in the absence of p53 on the maintenance of
p53 deficient status. Restoration of p53 activity (even
transient) led to complete regression of aggressive liver
tumors. Surprisingly, the carcinoma cells did not undergo
apoptosis, but instead displayed features of senescent-like
arrest. Although the arrested cells could maintain their
viability in vitro for a very long time, in vivo the tumors
regressed very rapidly. Expression profiling revealed that
the senescent tumor cells dramatically upregulated expres-
sion of pro-inflammatory leukocyte-attracting cytokines
and immune receptors. Activation of p53 resulted in infil-
tration of the tumor mass with immune cells (granulo-
cytes, macrophages and neutrophils), and application of
chemical inhibitors of macrophages and neutrophils sub-
stantially delayed tumor regression, revealing the impor-
tance of the innate immune system in removing senescent
cells. Analogous to results from T. Jacks lab, restoring p53
expression by silencing the shRNA silencer in B-cell lym-
phomas induces apoptotic death of tumor cells (R. Dick-
ins in Lowe lab). In summary, results from the Jacks, Lowe
and Evan labs using different conditional models all vali-
date p53 as an attractive therapeutic target.
In a related story, G. Evan presented evidence that p53 sta-
bilization due to the absence of Mdm2, even without
numerous modifications of the p53 protein induced by
stress, can rapidly induce senescence or apoptosis in an
adult animal. Protein levels of p53 are held in control by
its own target MDM2, which both squelches protein activ-
ity and down-regulates the protein levels via proteosomal
degradation. Null mutation of MDM2 leads to early
embryonic lethality unless rescued by p53 mutation [7,8].
Evan used the p53 ER-TAM system to restore p53 expres-
sion in the MDM2 knockout background in adulthood.
Restoration of p53 expression (even with a single dose of
tamoxifen) led to rapid apoptosis of all radiosensitive tis-
sues resulting in the death of the mice within 6 days. Inter-
estingly, radioresistant tissues maintain their viability,Cell Division 2006, 1:24 http://www.celldiv.com/content/1/1/24
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even when restoration of p53 expression was combined
with DNA damage. Instead of undergoing apoptosis, radi-
oresistant tissues underwent permanent proliferation
arrest, again highlighting intrinsic tissue-specificity in
p53-dependent cell fates.
It appears that in some cases "oncogene addiction" might
be tightly linked with "suppressor inactivation addiction".
L. Beverly (A. Capobianco lab) presented evidence that
Notch (which is mutated in 50% of human T-ALL) inacti-
vates p53 via repression of ARF-dependent MDM2 regula-
tion. Inactivation of Notch in spontaneous tumors arising
in mice that conditionally express Notch in the T-cell
compartment leads to rapid tumor regression via p53
dependent apoptosis. Importantly, p53 can be reactivated
using either irradiation or Nutlin even in the presence of
sustained Notch signaling, resulting in apoptosis and lym-
phoma regression. Thus, it is proposed that inhibition of
p53 activity by Notch signaling might be an important
step in the evolution and maintenance of the resulting T
cell malignancies. These findings provide a basis for the
high responsiveness of tumors with aberrant Notch sign-
aling to agents that re-activate p53, such as Nutlin or irra-
diation.
While others have shown that persistent expression of
Myc or Ras oncogenes is required for tumor maintenance
[9], K. Podsypanina (Varmus lab) demonstrated that in
mammary tumors resulting from coexpression of acti-
vated K-Ras with either Myc or Wnt-1, deinduction of K-
Ras (using tetracycline regulation) leads to rapid tumor
regression. Thus, oncogene addiction extends to contexts
where multiple defined initiating events are involved in
tumorigenesis, which is perhaps not surprising given that
oncogene addiction demonstrated in other models is on
the background of additional, albeit undefined, onco-
genic hits.
Finally, J. Jonkers reported on the development of condi-
tional mouse models of breast cancer. By K14-Cre
(expressed in epithelium) mediated deletion of p53,
together with either E-cadherin or BRCA1, they demon-
strated enhanced breast and skin carcinogenesis relative to
p53 deletion alone. However, the mechanisms may be
distinct, with E-cadherin loss abrogating detachment
induced apoptosis (anoikis) and BRCA1 loss resulting in
increased genomic instability. As the resulting adenocarci-
nomas resemble their human counterparts, these models
should be useful for testing therapeutics and drug resist-
ance mechanisms. Indeed, in their BRCA1/p53 mammary
tumor model, the development of drug resistance
appeared to derive from enhanced multidrug resistance
pump activity.
Cellular senescence
From its discovery, cellular senescence has been thought
to be an important barrier for cancer development. Recent
reports [10-14] have demonstrated the validity of such
speculation, establishing oncogene-induced cellular
senescence as a physiologically relevant tumor suppres-
sion mechanism. Presentations from the T. Jacks, G. Evan
and S. Lowe labs reviewed above highlighted that choice
of apoptosis vs. senescence is in large part cell-type spe-
cific.
While permanent senescent growth arrest has unambigu-
ous effects at the cellular level, it also leads to dramatic
changes in gene expression. The classical marker for senes-
cence has been the expression of senescence associated β-
galactosidase activity, and more recently senescence has
been associated with DNA damage foci [15]. One impor-
tant aspect of senescence associated gene expression
changes is the "secretory phenotype", involving substan-
tial increases in the secretion of biologically active mole-
cules including inflammatory cytokines, metalloproteases
and growth factors, which lead to non-cell autonomous
effects resulting from cellular senescence [16]. A number
of talks addressed the senescent cell secretion phenotype
and its biological significance, suggesting that the secre-
tory phenotype could either promote or suppress cancer
progression in different contexts.
Judith Campisi's lab has previously shown that the secre-
tory phenotype displayed by senescent fibroblasts can
substantially promote tumorigenesis by stimulating the
proliferation and tumorigenicity of pre-malignant cells
[17,18]. Her presentation explored a more molecular
characterization of this phenotype. Microarray data indi-
cated that the secretory phenotype is shared by senescent
fibroblasts from different tissues and donor ages, as well
as senescent endothelial and mammary epithelial cells.
However, the intensity of the secretory phenotype did vary
with different senescence-causing stimuli. Interestingly,
disruption of p53 in primary human fibroblasts that
underwent replicative senescence leads to dramatic fur-
ther up-regulation of the secretory phenotype coinciding
with the expected reversal of senescence, revealing a non-
cell autonomous tumor suppressor function of p53.
Other reports however, implied anti-tumor functions of
the secretion phenotype. As described above, studies by
W. Xue and  S. Lowe using a hepatocarcinoma model
revealed that secretion of inflammatory cytokines mobi-
lized the innate immune system to eliminate senescent
tumor cells, thus perhaps preventing the emergence of
mutants escaping the senescence. D. Peeper's lab reported
an important role of cytokines secreted by senescent cells
in maintaining the senescent phenotype. This group
recently published that human naevi (benign tumors ofCell Division 2006, 1:24 http://www.celldiv.com/content/1/1/24
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melanocytic origin that can remain in unaltered state for
decades and often express BRAFV600E) display senescence-
like growth arrest [11]. In his current talk, Peeper
described studies to identify mechanisms responsible for
maintaining the irreversibility of arrest as well as events
that allow cells to escape the senescent-like arrest triggered
by oncogene expression (BRAFV600E  expressed in p16
mutant fibroblasts). Gene-expression arrays identified
potent induction of interleukins (IL-6, IL-1α, β). Impor-
tantly, they showed that expression of IL-6 and its receptor
were required for maintenance of the senescent pheno-
type. C/EBPβ was identified as a common denominator
responsible for induction of cytokines and maintenance
of senescence. The use of bar-coded shRNA library screen
for senescence-escape mutants allowed identification of
additional genes implicated in maintenance of senes-
cence, and thus potentially oncogenic events that can
allow malignant transformation.
Tumor evolution
The last few decades have seen dramatic progress in
advancing a gene-centered understanding of molecular
mechanisms of cancer development, including elucida-
tion of pathways that regulate cellular proliferation, apop-
tosis and growth arrest. While better understanding of
cell-intrinsic mechanisms and pathways is undoubtedly a
step toward better clinical strategies, excessive "gene-cen-
trism" initially gave insufficient attention to the fact that
the evolution of cancer is shaped not only by cell-intrinsic
events, but also to a large extent by the environment. M.
Bissell overviewed critical roles that the extracellular envi-
ronment has on the development of cancers, highlighting
evidence that alteration of physiological communication
of cancer cells with the environment is not only a required
step in cancer evolution, but also that the disruption of
this communication impacts other hallmarks of cancer,
such as proliferation and genetic instability [19]. Impor-
tantly, restoration of normal communication at least in
some cases can lead to dramatic reversal of cancer pheno-
types. Moreover, macroscopic structure and polarity have
a substantial impact on cancer biology, evolution and
outcomes of therapy. Therefore, understanding the mech-
anisms that allow communication between macroscopic
structures and microscopic events is of great importance.
Bissell also presented interesting studies of epithelial
branching development using 3-d gels of set microscopic
shapes. Macroscopic structure was found to impose strict
restraints on local outgrowth of cells. Combination of
bioinformatics methods and experimental approaches
allowed identification of a TGF-β inhibitory gradient as
being the major factor responsible for macroscopic struc-
ture regulation of local morphogenesis.
Cancer progression can undoubtedly be regarded from
the perspective of principles of Darwinian evolution. In
order for an oncogenic mutation to be selected it should
increase the fitness of the cell. But the fitness of a cell is
determined by not only cell-intrinsic properties but also
by the environment where the cell exists and by the rela-
tive fitness of other cells in the same population, since
selection works by competition. J. DeGregori's lab has
previously demonstrated that a background of impaired
cellular proliferation engendered by drugs or genetic alter-
ations substantially increases the selective advantage pro-
vided by the Bcr-Abl oncogenic translocation, resulting in
dramatic increases in leukemogenesis [20]. Aging is the
single strongest prognostic factor for cancer predisposi-
tion, which has largely been explained by accumulating
mutations with age. Still, age is also clearly associated with
the decreased function of progenitor cells in many tissues,
suggesting the possibility that "poor fitness" of cell popu-
lations might be a factor contributing to the dramatic
increase in the onset of malignancies observed with
advanced age. A. Marusyk from the DeGregori lab pre-
sented evidence supporting the validity of this hypothesis.
Using a bone marrow transplantation model for leukemia
initiation, Bcr-Abl was demonstrated to provide a much
stronger selective advantage in the background of aged
hematopoiesis compared to the background of young
hematopoiesis, leading to a substantial increase in leuke-
mias. Importantly, this age-dependence appeared largely
non-cell autonomous, since introduction of young com-
petitors efficiently reversed the competitive advantage
conferred by Bcr-Abl expression. These findings reveal a
novel factor contributing to age-related increase in cancer
incidence, highlighting the importance of non-cell auton-
omous forces driving cancer evolution.
While experiments described above showed that muta-
tions (such as in p53) involved in the genesis of cancer
can also be required for tumor maintenance, an interest-
ing presentation from B. Amati's lab suggest that tumors
could select for the restoration of partial loss of function
events that favored tumor initiation. C. Gorrini presented
evidence that the acetyl-transferase Tip60 is important for
Myc-induced double-stranded DNA damage response, as
heterozygosity for Tip60 substantially attenuates activa-
tion of p53 and ATM. Tip60 heterozygosity accelerates the
onset of Eμ-Myc driven lymphomagensis, suggesting the
importance of DNA damage response in the suppression
of tumorigenesis. Although Tip60 heterozygosity prevents
activating phosphorylation of p53, lymphomas originat-
ing in a Tip60+/- background still retain selective pressure
to lose p53. Interestingly, while Tip60 heterozygosity dra-
matically shortens the onset of lymphomas, the lym-
phoma cells duplicate the remaining Tip60 allele,
restoring Tip60 expression to wildtype levels. These stud-
ies suggest an interesting scenario, whereby haploinsuffi-
ciency is important in the initial stages of tumorCell Division 2006, 1:24 http://www.celldiv.com/content/1/1/24
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development, but at some point in cancer evolution there
is selective pressure to restore gene function.
Evolution of cancer involves acquisition of multiple new
traits, the so called "hallmarks of cancer" [21]. Each hall-
mark is traditionally though to be associated with new
alterations in the cancer cell genome. Using the reversible
transgenic model to explore c-Myc driven oncogenesis in
pancreatic β-cells, G. Evan has previously shown that acti-
vation of Myc on the background of suppressed apoptosis
not only drives cell proliferation and expansion of β-cells,
but also concomitantly induces features of advanced neo-
plasia such as increased invasiveness and vascularization
[22]. Here Evan presented findings revealing the mecha-
nisms of increased angiogenesis. Myc expression led to
translocation of VEGF from extra-cellular matrix to vessel
epithelia [23]. This re-localization was dependent on Myc-
induced increases in production of IL-1β and inflamma-
tory cytokines that recruited mast cells to adjacent stroma.
Prevention of migration of mast cells efficiently blocked
angiogenesis, leading to hypoxia induction in Myc-
expressing β-cells and blockade of islet expansion. These
findings highlight the importance of communication
within the local environment in c-Myc driven angiogen-
esis and oncogenesis.
Reducing immune system tolerance to target 
cancers
J. Allison presented a report of the successful mobiliza-
tion of the immune system to target cancer cells by capi-
talizing on a better understanding of the complex
regulatory pathways that coordinate T-cell immune
responses. The immune system is extremely efficient in
eliminating cells that express foreign or abnormal pro-
teins. Extensive research efforts have been applied to har-
ness the immune system to recognize and eliminate
cancer cells, and although T-cells are capable of recogniz-
ing tumor-specific antigens, attempts to mobilize T-cells
to kill tumor cells have thus far met with very limited suc-
cess. Part of the problem appears to lie in the existence of
intricate control mechanisms that negatively regulate T-
cell proliferation in order to prevent autoimmune disease.
One such control mechanism involves upregulation of
CTLA-4 receptor in response to antigen receptor signaling
[24]. CTLA-4 upregulation antagonizes T-cell signaling,
proliferation and activation. While CTLA-4 protein nor-
mally has a very short half-life, chronic antigen presenta-
tion leads to maintained CTLA-4 expression and thus
continuous inhibition of T-cell response. Tumors may
present such chronic stimulation which can lead to host
tolerance of the tumor. Allison presented evidence that
blocking CTLA-4 signaling can dramatically improve T-
cell mediated killing of tumor cells, leading to develop-
ment of effective clinical strategies. While some tumors
have intrinsically poor immunogenicity and avoid
immune response even when CTLA-4 is blocked, combin-
ing CTLA-4 blockade with vaccination against tumor-spe-
cific proteins and/or with therapies that lead to increased
death of tumor cells (which also boost presentation of
tumor proteins by antigen-presenting cells) can substan-
tially improve the recognition and elimination of such
tumors. In fact, durable, objective responses have been
obtained in melanoma, renal, prostate, and ovarian can-
cer in clinical trials.
The results presented above highlight substantial progress
in developing and refining experimental models of can-
cers. The studies reviewed here emphasize the importance
of the research shift towards animal modeling in order to
understand not what might possibly be happening but what
really is happening (to paraphrase M. Bissel). In addition,
the cancer field is showing steady progress towards a bet-
ter understanding of the evolutionary forces that drive
tumorigenesis, the intricate and inherent tumor suppres-
sive mechanisms that prevent cancer, and the alterations
that allow tumor cells to escape these controls. Building
upon this knowledge will allow a more intelligent identi-
fication of targets for anti-cancer therapies and strategies
for cancer prevention.
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